SEC Form 4 · accession 0000899243-15-001415
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dennis Karl Huang
Officer — SVP and Chief Tech Ops Officer
Period of report
Jul 16, 2015
Accepted (ET)
Jul 20, 2015 · 5:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $124.87 | Jul 16, 2015 | A | 15,000 | A | — | Jul 15, 2025 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The option shall vest with respect to 1/4th of the underlying shares on July 13, 2016 and then with respect to 1/48th of the underlying shares monthly thereafter.